AUM001
mRNA translation inhibitor
AUM001 is a selective, potent, safe, and synergistic MNK inhibitor, with novel mechanism of action for cancer therapy, AUM001 addresses three major signaling pathways: RAS-MAPK, PI3K and MYC. AUM001 is currently in Phase II. It has the independent IO activity and stimulates the innate immune system, encourages T-cell proliferation, prevents T-cell exhaustion to combat tumor cells.
MECHANISM OF ACTION
MNK inhibition interferes with phosphorylation of eIF4E, a critical element of the RNA to protein translation machinery, thereby hindering the translation of oncogenic signaling pathways and overcoming upstream resistance mechanisms. Increased MNK activity correlates with higher expression of oncogenes involved in migration, invasion, and stem cell renewal.
